羚锐制药(600285.SH)发布2025年半年度报告，报告期内，公司实现营业收入20.99亿元，同比增长 10.14%。实现归属于上市公司股东的净利润4.74亿元，同比增长14.85%。实现归属于上市公司股东的扣 除非经常性损益的净利润4.42亿元，同比增长12.28%。基本每股收益0.836元。 ...

人民财讯8月19日电，羚锐制药（600285）8月19日晚间披露2025年半年报，公司上半年实现营业收入 20.99亿元，同比增长10.14%；归母净利润为4.74亿元，同比增长14.85%。基本每股收益0.836元。 ...

格隆汇8月19日丨羚锐制药(600285.SH)公布2025年半年度报告，报告期实现营业收入20.99亿元，同比增 长10.14%；归属于上市公司股东的净利润4.74亿元，同比增长14.85%；归属于上市公司股东的扣除非经 常性损益的净利润4.42亿元，同比增长12.28%；基本每股收益0.836元。 ...

Group 1 - The company reported a revenue of 2.099 billion yuan for the first half of 2025, representing a year-on-year growth of 10.14% [1] - The net profit for the same period was 474 million yuan, showing a year-on-year increase of 14.85% [1] - The basic earnings per share reached 0.836 yuan, which is a year-on-year growth of 14.21% [1]

Summary of Key Points Core Viewpoint - The financing activities and capital flow of Lingrui Pharmaceutical indicate a mixed performance, with significant net buying but also notable outflows in recent days [1]. Financing Activities - Lingrui Pharmaceutical had a net financing inflow of 16.7777 million yuan last week, ranking 477th in the market [1]. - The total financing amount for the week was 117 million yuan, while the repayment amount was 99.8371 million yuan [1]. Capital Flow - Over the past 5 days, the main capital outflow from Lingrui Pharmaceutical was 52.8221 million yuan, with a decline of 6.54% during this period [1]. - In the last 10 days, the main capital outflow was 52.6537 million yuan, reflecting a decrease of 3.4% [1]. Company Profile - Lingrui Pharmaceutical, established in 1999, is located in Xinyang and primarily engages in the pharmaceutical manufacturing industry [1]. - The company has a registered capital of 567.115486 million yuan, which is also its paid-in capital [1]. - The legal representative of the company is Xiong Wei [1]. Investment and Intellectual Property - Lingrui Pharmaceutical has invested in 14 external enterprises and participated in 5,000 bidding projects [1]. - The company holds 287 trademark registrations and 249 patents, along with 356 administrative licenses [1].

Core Viewpoint - The stock price of Lingrui Pharmaceutical remains stable at 22.83 yuan as of August 15, 2025, with a total market capitalization of 12.947 billion yuan [1] Company Overview - Lingrui Pharmaceutical specializes in the research, development, production, and sales of traditional Chinese medicine, offering various dosage forms including plasters, tablets, and capsules [1] - The company operates in sectors such as traditional Chinese medicine, Henan province, and innovative drugs [1] Market Activity - On the trading day, the company recorded a transaction volume of 158 million yuan and a turnover rate of 1.22% [1] - An upcoming semi-annual performance briefing is scheduled for August 26, 2025, which investors are encouraged to follow [1]

证券日报网讯8月15日晚间，羚锐制药（600285）发布公告称，公司计划于2025年8月26日(星期二)16： 00-17：00举行2025年半年度业绩说明会。 ...

证券代码：600285 证券简称：羚锐制药 公告编号：2025-029 号 河南羚锐制药股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 8 月 19 日（星期二） 至 8 月 25 日（星期一）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 600285@lingrui.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 河南羚锐制药股份有限公司（以下简称"公司"）将于 2025 年 8 月 20 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半 年度经营成果、财务状况，公司计划于 2025 年 8 月 26 日（星期二）16:00-17:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说 ...

Group 1 - The fentanyl concept sector increased by 1.24%, ranking second in terms of sector gains, with one stock, Botao Bio, hitting a 20% limit up [1][2] - The main stocks in the fentanyl sector experienced mixed performance, with notable declines in Renfu Pharmaceutical, Oriental Bio, and Guoyao Modern, which fell by 3.16%, 2.59%, and 1.23% respectively [1][2] Group 2 - The fentanyl concept sector saw a net inflow of 50 million yuan, with four stocks receiving significant inflows, led by Botao Bio with a net inflow of 51.6459 million yuan [2][3] - The net inflow ratios for Botao Bio, Oriental Bio, and Wanfu Bio were 11.85%, 5.85%, and 5.04% respectively, indicating strong interest from main funds [3]

Group 1 - The insurance institutions and pension accounts have significantly increased their holdings in listed companies, with a total of 3.49 billion shares valued at 12.843 billion yuan as of August 17 [1] - Pension accounts appeared in the top ten shareholders of 33 stocks in the second quarter, with a total holding of 3.26 billion shares valued at 5.392 billion yuan [1] - The largest holding by pension accounts is in Focus Media, with approximately 150 million shares, while Shengtu Mining follows with 28.63 million shares [1] Group 2 - The pension accounts have a significant presence in the pharmaceutical and electronics sectors, with notable holdings in companies like Aiyingshi and Yuhua Tian [2] - The Basic Pension Insurance Fund 16041 combination increased its holdings in Jizhi Technology and Nuohua Zhiyuan by 2.4281 million shares and 1.2976 million shares, respectively [2] - The Basic Pension Insurance Fund 16022 combination also increased its stake in Blue Sky Technology by 4.8997 million shares [2] Group 3 - Approximately 20 companies held by pension accounts reported net profit growth, with Yongxing Materials showing a remarkable increase of 647.64% in net profit [3] - Sunlord Electronics, despite a decline in revenue and net profit, was newly held by the Basic Pension Insurance Fund 802 combination with a holding of 12.5318 million shares valued at 340 million yuan [3] - Lingrui Pharmaceutical saw a new holding of 13.6028 million shares from the Basic Pension Insurance Fund 15022 combination, with a market value of 170 million yuan [3] Group 4 - More than ten insurance institutions entered the top ten shareholders of several listed companies in the second quarter, focusing on manufacturing and energy sectors [4] - Taikang Life's products became top shareholders in companies like Lansi Heavy Industry and Jinqiao Huazhong [4] - Major companies like China Unicom and WuXi AppTec remain favored by institutional investors, with market values of 11.039 billion yuan and 5.510 billion yuan, respectively [4]